C. Andrew Kistler, MD, PharmD

Andy authors Cancer Therapy Advisor's "In the Clinic" column. He is a gastroenterologist with interests in GI oncology, immunotherapy, the gut microbiome, and clinical pharmacology.

All articles by C. Andrew Kistler, MD, PharmD

GI Illness

Postinfectious IBS: What to Look For

C. Andrew Kistler, MD, PharmD

November 17, 2021

Given the overall prevalence of irritable bowel syndrome, it is important for clinicians to be able to distinguish postinfectious irritable bowel syndrome from its other subtypes.

General Infectious Disease

FMT: Can It Improve Immunotherapy Outcomes?

C. Andrew Kistler, MD, PharmD

October 22, 2021

Further research is warranted to understand the potential ways fecal microbiota transplantations may improve patients’ responses to immunotherapy.

COVID19

COVID-19 and IBD: Impact of Disease State and Biologics

C. Andrew Kistler, MD, PharmD

May 25, 2021

In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.

HIV/AIDS

HIV and Inflammatory Bowel Disease: A Unique Patient Population

C. Andrew Kistler, MD, PharmD

April 23, 2021

The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.

Next post in HIV/AIDS

C. Andrew Kistler, MD, PharmD

All articles by C. Andrew Kistler, MD, PharmD

Postinfectious IBS: What to Look For

FMT: Can It Improve Immunotherapy Outcomes?

COVID-19 and IBD: Impact of Disease State and Biologics

HIV and Inflammatory Bowel Disease: A Unique Patient Population

Untreated Genital Tract Inflammation Plays Role in HIV Transmission